Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
May 22, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in Orphazymes shares made
Read moreOrphazyme’s arimoclomol receives US Fast Track Designation in Amyotrophic Lateral Sclerosis
May 22, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, announces that the Company has received Fast Track Designation from the US Food and Drug Administration (FDA) for the development of arimoclomol for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Orphazymes arimoclomol receives us fast track design
Read moreCapital increase of 4,616 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units
Apr 20, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that a share capital increase has been registered with the Danish Business Authority as a result of the exercise of Restricted Share Units by board members. A total of 4,616 shares of nominally DKK 1 each have been issued by the Company.
Capital increase of 4616 shares in Orphazyme
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Apr 17, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in Orphazymes shares made
Read moreResolutions passed at the Annual General Meeting
Mar 26, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today held its Annual General Meeting, at which the Annual General Meeting.
Resolutions passed at the annual general meeting
Read moreOrphazyme publishes listing prospectus in connection with listing of shares
Mar 16, 2020
Orphazyme A/S (ORPHA.CO), a biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces the publication of a listing prospectus (the “Listing Prospectus”) prepared for the purposes of admitting 3,071,673 shares of nominal value DKK 1 each (the “Listing Shares”) to trading and official listing on Nasdaq Copenhagen A/S under the permanent ISIN code DK0060910917 (the “Listing”).
Orphazyme publishes listing prospectus ...
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Mar 11, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in Orphazymes shares made
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Mar 10, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in orphazyme s shares made
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Mar 4, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in orphazymes shares made
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Mar 3, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in orphazymes shares made
Read more